LRP6 and prostate cancer: As shown in Figure 3A, niclosamide was able to suppress LRP6 expression and phosphorylation in all four cancer cell lines, indicating that niclosamide can repress Wnt/β-catenin signaling in breast and prostate cancer cells by suppressing LRP6 expression.